V oltage-gated Ca 2ϩ channels regulate the intracellular Ca 2ϩ concentration and thereby contribute to Ca 2ϩ signaling in numerous cell types. They are classified as either high-voltage activated or low-voltage activated. High-voltage-activated channels include L-, N-, P/Q-, and R-types, 1, 2 and low-voltage-activated channels are designated as T-type. 3 Voltage-gated Ca 2ϩ channels also serve as important drug targets, with most therapeutically useful Ca 2ϩ channel blockers targeting L-type channels. These compounds (eg, isradipine) are widely prescribed as antihypertensive drugs because they block Ca 2ϩ influx via Ca v 1.2 L-type Ca 2ϩ channels into smooth muscle cells, which constitutes the key determinant of vascular smooth muscle (VSM) tone and blood pressure. 4, 5 Ca v 1.2 L-type Ca 2ϩ channels are not the only class of voltage-gated Ca 2ϩ channels in VSM. The presence of T-type Ca 2ϩ channels in vascular smooth muscle has been suggested using electrophysiological and molecular biological techniques. 3,6 -8 The development and characterization of mibefradil (also termed Ro 40-5967), an antihypertensive drug thought to selectively block T-type Ca 2ϩ channels at the concentrations having a significant effect on blood pressure (Ϸ1 to 10 mol/ L), supported the hypothesis that inhibition of VSM T-type Ca 2ϩ channels would produce vasorelaxation. 6 In addition, other studies have confirmed the relative selectivity (eg, Ϸ10-to 30-fold for T-type over L-type channels) and, thus, the usability of mibefradil as a T-type Ca 2ϩ channel blocking agent for functional studies in the cardiovascular system. 9, 10 Combined with the antihypertensive and direct vasodilating effects mibefradil on isolated vessels, 11-14 a significant body of evidence has been accumulated suggesting the presence and function of T-type Ca 2ϩ channels in regulating vascular contraction and, thus, blood pressure. However, in stark contrast to these findings, a genetic loss-of-function model, a mouse lacking the Ca v 3.2 T-type Ca 2ϩ channel, surprisingly demonstrated that Ca 2ϩ influx through VSM T-type Ca 2ϩ channels is an essential mediator of normal relaxation, not contraction, of coronary arteries. 15 Given these puzzling results on the role of T-type Ca 2ϩ channels for VSM contractility and blood pressure regulation, we hypothesized that the vasorelaxing effect of mibefradil might not be explained by a block of T-type Ca 2ϩ channels but of VSM Ca v 1.2 L-type Ca 2ϩ channels. To dissect the function of these potential vascular receptors for mibefradil, we used transgenic mice deficient in the VSM L-type Ca 2ϩ channel Ca v 1.2, 4 the major Ca 2ϩ entry pathway in vascular smooth muscle cells. 5 In this model, the biophysical and pharmacological properties of the channels that remain expressed, here the Ca v 3.x T-type Ca 2ϩ channels, can be investigated in isolation.
Materials and Methods
All experiments were conducted in accordance with the Guide for the Use and Care of Laboratory Animals and approved by the Regierung von Oberbayern.
Conditional Inactivation of the Ca V 1.2 Gene in Smooth Muscle Cells
Generation and characterization of the smooth-muscle specific Ca v 1.2-deficient mice were described previously. 4, 16 Two different CACNA1C (ϷCa v 1.2) alleles were generated by Cre-mediated recombination in embryonic stem cells (L1 and L2). In L1, exons 14 and 15, which encode the IIS5 and IIS6 transmembrane segments and the pore loop in domain II, were deleted. Additionally, this deletion caused an incorrect splicing from exon 13 to part of an intron upstream of exon 16 and thereby generated a premature stop codon in exon 16 
RT-PCR on mRNA of Aortae and Resistance Vessels (Arteria Tibialis)
Aortae and A tibialis were isolated and cleaned of connective tissue. Poly(A) mRNA was isolated from the vessels using Dynabeads Oligo(dT) 25 The mRNA was eluted with diethylpyrocarbonate-treated water. Oligo-dT primers and Superscript Reverse Transcriptase II (Life Technologies) were used for cDNA synthesis. Using the following gene-specific, intron-spanning primers, PCR amplification (40 cycles) was performed:
Isolation of Single Smooth Muscle Cells
The vessel dissection and cell isolation procedures were slightly modified from procedures described previously. 4, 18 Briefly, control and Ca V 1.2 SMAKO littermates were killed by cervical dislocation. Arteries were cleaned in either ice-cold PBS or physiological salt solution (in mmol/L: 130 NaCl, 5.9 KCl, 1.2 MgCl 2 , 11 glucose, 10 HEPES; pH 7.4). The arteries were cut into 2 to 4 pieces and equilibrated in PSS or transferred into 0.5 mL Ca-free solution (in mmol/L: 55 NaCl, 80 Na-glutamate, 5.6 KCl, 2 MgCl 2 , 10 glucose, 10 HEPES; pH 7.4). After a 10-minute equilibration at 37°C, the artery segments were placed into enzyme solution 1 (Ca-free solution containing 1 mg/mL albumin, 0.7 mg/mL papain, and 1 mg/mL dithiothreitol) and digested for 30 minutes. The vessels were then transferred into enzyme solution 2 (containing 1 mg/mL albumin, 0.05 mmol/L CaCl 2 , 1 mg/mL hyaluronidase, and 1 mg/mL collagenase F/H [70:30]) and digested for another 10 to 12 minutes. The tissue was subsequently washed for 10 minutes in PSS or Ca-free solution 1 containing 1 mg/mL albumin. Single smooth muscle cells were obtained by trituration and stored in the above solution before use at 4°C. Cells were used for 8 to 24 hours.
Electrophysiology
Membrane potentials and potassium currents were determined in single A tibialis smooth muscle cells from control and Ca V 1. 
Telemetric Blood Pressure Recordings
Male knockout and control littermate mice (8 to 12 weeks old) were treated with tamoxifen solution (Sigma) by IP injection once a day for 5 days at a dosage of 1 mg/d. Animals were kept on a 12-hour light/dark cycle. Blood pressure signals from the aortic arch were measured in conscious, unrestrained animals with surgically implanted, miniaturized telemetry devices (Datascience Corp). For long-term measurements of mean arterial blood pressure (MAP), mice were implanted with the transmitter, allowed to recover for 2 weeks, and then treated with tamoxifen. Immediately after implantation of the transmitter, mice were returned to their home cages (placed on top of telemetry receivers), where they continued to be monitored daily throughout the study for general condition, body weight, food and water intake, state of surgical wound healing, and any signs of morbidity. MAP, heart rate, and locomotor activity were recorded continuously for 28 days after tamoxifen injection. For short-term measurements of MAP, the transmitters were implanted into mice pretreated with tamoxifen (21 to 28 days before) and the animals were allowed to recover from anesthesia and then were directly measured when fully awake. Vasoactive compounds were applied IP as a bolus (200 L) in PBS. Sixty-second MAP recordings were obtained every 90 sec for 15 minutes before and until 120 minutes after drug administration. Recordings obtained after a stable drug effect was observed were used for statistical analysis.
Perfused Hindlimb
After death, the infrarenal aorta was prepared, and a catheter (1 mm; Hugo Sachs, Germany) was introduced, advanced to the iliac arteries, and tied with a 6/0 prolene stitch (Ethicon). The inferior caval vein was slit open longitudinally to prevent venous congestion. A roller pump was used to perfuse the hindlimb constantly with filtered Krebs-Henseleit (KH) solution. A pressure transducer and a compliance chamber were connected to a side port of the perfusion system. The flow rate was gradually increased to achieve a perfusion pressure of 100 mm Hg. At this perfusion pressure, a considerable amount of spontaneous myogenic tone is present, which made preconstriction unnecessary. When a substance produced a pronounced change in resistance, flow rate was adjusted. When a stable pressure plateau was reached, phenylephrine (PE) was applied in increasing concentrations as a bolus (200 L) in KH solution, in the presence or absence of inhibitors (mibefradil, Ni 2ϩ ) in the perfusate. For inhibitor studies, agonist-induced responses were recorded in the absence and then in the presence of the inhibitor to facilitate paired comparison of the results. Vasodilator responses were measured as changes in perfusion pressure.
Data Analysis
Data are given as mean valuesϮSEM. Statistical significances were evaluated by either ANOVA followed by Dunnet's ad hoc tests for unpaired comparisons or by paired Student's t test.
Results and Discussion
To investigate how the effects of mibefradil on blood pressure are mediated without the need to rely on potentially nonselective L-type Ca 2ϩ channel blockers, we used a third generation, time-and tissue-specific conditional knockout model with an inactivation of the CACNA1C (ϷCa v 1.2) gene. These animals (Ca v 1.2 SMAKO mice) express the tamoxifendependent CreER T2 recombinase under the control of the endogenous smooth muscle-specific SM22 gene promoter. 4 Treatment of these premutant mice with tamoxifen activates the CreER T2 recombinase and results in effective ablation of Ca v 1.2 selectively in smooth muscle in vivo (see Materials and Methods for details).
T-Type Ca 2؉ Channels Are Present in Murine Aorta and Resistance Vessels
As a prerequisite for the functional experiments, we first wanted to characterize the expression of the 3 T-type Ca 2ϩ channel subunits in murine aortae and resistance vessels (A tibialis). RNA was extracted from both vessel types of 3 mice and analyzed along with RNA obtained from total brain, which served as a positive control. Amplification products for all three T-type Ca 2ϩ channels Ca v 3.1 to Ca v 3.3 were detected in brain by RT-PCR amplification for 40 cycles ( Figure 1A) . Sequencing corroborated the correct identity of the amplification products. We observed significant expression of Ca v 3.2 mRNA in both aortae and tibialis vessels ( Figure 1B  and 1C) . Ca v 3.3 transcripts were weakly detectable in aortae ( Figure 1D ) and more strongly expressed in A tibialis ( Figure  1B) . No amplification products were observed for Ca v 3.1 mRNA in both vessel types. 
No Downregulation of T-type

Perfused Hindlimb Experiments
Pressure-induced vasoconstriction or myogenic tone of small arteries and arterioles is a major component in the control of vascular resistance and, thus, blood pressure. 5 Therefore, we first analyzed the effect of mibefradil on peripheral resistance in control and Ca v 1.2 SMAKO mice resistance vessels (arterioles and capillaries) using the perfused hindlimb system. Flow rate was gradually increased to achieve a perfusion pressure of approximately 100 mm Hg; at this perfusion pressure, a considerable amount of spontaneous myogenic tone is present. 19 Resistance at 100 mm Hg perfusion pressure was reduced to Ϸ60% in Ca v 1.2 SMAKO compared with control hindlimbs (Figure 2A) , indicating the loss of autoregulatory myogenic tone in animals deficient for Ca v 1.2. 4 Mibefradil treatment of control preparations using a concentration in the perfusate supposed to be specific for T-type Ca 2ϩ channels 6,14 and equivalent to the therapeutic plasma level in vivo 8 21 (Ϸ10 mol/L), this result may suggest minimal contribution of T-type Ca 2ϩ channels to peripheral resistance in hindlimb vessels.
Arterial blood pressure is not only determined by autoregulatory myogenic mechanisms but also by an interplay of vasoconstrictors (most importantly angiotensin II and norepinephrine) and vasodilators. 5 Therefore, we tested the effect of mibefradil on contractile responses to ␣-adrenergic stimulation. Perfusion pressure changes to bolus application of 200 L of 1 mmol/L PE were blunted by mibefradil treatment in control mice (contractile response in control mice: 52Ϯ4%; in control miceϩmibefradil: 30Ϯ3%; PϽ0.01) ( Figure 2B) Figure 2C ). These results make it unlikely that block of T-type Ca 2ϩ channels plays a role in the action of mibefradil on the ␣-adrenergic vasoconstrictor response in the microvasculature.
Telemetric Blood Pressure Measurements
Given that the vasodilating effect of mibefradil in skeletal muscle resistance arteries was evidently mediated by the Ca v 1.2 channel, we next examined the in vivo effects of mibefradil on blood pressure in awake, freely moving mice. We followed the changes in MAP in control and Ca v 1.2 SMAKO mice by telemetry ( Figure 3A ). In general, as shown previously, 4 inactivation of the Ca v 1.2 gene resulted in a decrease of MAP form 118Ϯ4 to 85Ϯ3 mm Hg. The MAP was decreased in control mice by 38Ϯ2.5 mm Hg after IP injection of increasing doses of mibefradil (1,25 g/kg body weight mibefradil to 1.25 mg/kg body weight mibefradil; Figure 3A and 3B). Although this drop in MAP indicates the efficiency of mibefradil as an antihypertensive agent, mibefradil had no effect on blood pressure in mice lacking the L-type Ca 2ϩ channel Ca v 1.2 ( Figure 3A and 3C 
Conclusion
Although the properties of cloned Ca v 3.x T-type Ca 2ϩ channels are, in principle, consistent with possible roles for these channels in Ca 2ϩ homeostasis of smooth muscle cells, their function in vascular tissue is unclear. The antihypertensive actions of mibefradil, a compound thought to selectively block T-type Ca 2ϩ channels at therapeutic concentrations (Ϸ1 to 10 mol/L), suggested the hypothesis that inhibition of VSM T-type Ca 2ϩ channels would produce vasorelaxation. 6 Because of the existence of multiple receptors for this drug (for a review, see Perez-Reyes 22 ), it is difficult to single out the correct in vivo mechanism for the antihypertensive effects of mibefradil.
Here, we have investigated whether mibefradil achieves its beneficial vascular effects by a block of L-or T-type Ca 2ϩ channels. We used a spatiotemporally controlled Cre/lox mouse model specifically lacking 1 of the putative receptors of mibefradil, the Ca v 1.2 L-type Ca 2ϩ channel, in the vessels. In this model, the pharmacological properties of the channels that remain expressed, here the Ca v 3.x T-type Ca 2ϩ channels, can be investigated free from interference by the Ca v 1.2 channel.
Our major findings were as follows: (1) mibefradil lowers MAP and attenuates peripheral resistance in mice; (2) although in vitro studies have reported a 10-to 30 fold selectivity of mibefradil for T-type voltage-gated channels, 6 These results do not rule out a modest contribution of T-type Ca 2ϩ channels in the regulation of vascular tone, although they suggest that the contribution of T-type channels to the contraction of resistance vessels is minimal. This notion is in excellent agreement with the recent finding that deletion of the Ca v 3.2 T-type channels impaired coronary relaxation, not contraction, in mice. 15 Given the controversial literature on the role of T-type Ca 2ϩ channel as a target for cardiovascular pathology, 6, 14, 15, [22] [23] [24] [25] studies on transgenic mice lacking T-type Ca 2ϩ channels without the need to rely on the unspecific blocker mibefradil might help to further clarify the functional role of these channels. 
